Epithelial-to-mesenchymal transition (EMT) processes endow epithelial cells with enhanced migratory/invasive properties and are therefore likely to contribute to tumor invasion and metastatic spread. Because of the difficulty in following EMT processes in human tumors, we have developed and characterized an animal model with transplantable human breast tumor cells (MDA-MB-468) uniquely showing spontaneous EMT events to occur. Using vimentin as a marker of EMT, heterogeneity was revealed in the primary MDA-MB-468 xenografts with vimentin-negative and vimentin-positive areas, as also observed on clinical human invasive breast tumor specimens. Reverse transcriptase-PCR after microdissection of these populations from the xenografts revealed EMT traits in the vimentin-positive zones characterized by enhanced 'mesenchymal gene' expression (Snail, Slug and fibroblast-specific protein-1) and diminished expression of epithelial molecules (E-cadherin, ZO-3 and JAM-A). Circulating tumor cells (CTCs) were detected in the blood as soon as 8 days after s.c. injection, and lung metastases developed in all animals injected as examined by in vivo imaging analyses and histology. High levels of vimentin RNA were detected in CTCs by reverse transcriptasequantitative PCR as well as, to a lesser extent, Snail and Slug RNA. Von Willebrand Factor/vimentin double immunostainings further showed that tumor cells in vascular tumoral emboli all expressed vimentin. Tumoral emboli in the lungs also expressed vimentin whereas macrometastases displayed heterogenous vimentin expression, as seen in the primary xenografts. In conclusion, our data uniquely demonstrate in an in vivo context that EMT occurs in the primary tumors, and associates with an enhanced ability to intravasate and generate CTCs. They further suggest that mesenchymal-to-epithelial phenomena occur in secondary organs, facilitating the metastatic growth.
Introduction
Metastasis formation from epithelial tumors progresses through various steps including invasion of adjacent tissues, generation of circulating tumor cells (CTCs), intravasation into the vasculature, survival in the vasculature, extravasation and growth at secondary sites. During this metastatic cascade, epithelial tumor cells undergo many phenotypic changes enabling a few of them to overcome these successive barriers and develop overt metastases in secondary organs.
Increasing data have shown that epithelial-to-mesenchymal transition (EMT) processes contribute to the invasive conversion of otherwise static epithelial cells (Yang and Weinberg, 2008; Kalluri and Weinberg, 2009; Klymkowsky and Savagner, 2009; Polyak and Weinberg, 2009; Thiery et al., 2009) . A wide spectrum of changes occurs during EMT processes, generating many intermediate phenotypes between epithelial and mesenchymal states. Nevertheless, several molecular EMT markers and mediators have been identified, which are common to most physiological and pathological EMT processes (Yang and Weinberg, 2008; Kalluri and Weinberg, 2009; Polyak and Weinberg, 2009 ). Among mesenchymal markers that are frequently expressed during EMT, one can observe the induction of vimentin, a-smooth muscle actin, fibroblast-specific protein 1 and specific matrix metalloproteases. Regarding the loss of epithelial features, a loosening of intercellular adhesion is frequently observed, with a corresponding reorganization of adherens junctions and tight junctions and increased cell motility. The reorganization of intercellular junctions can also initiate signaling events through the relocalization of molecular adaptors (such as b-catenin or ZO-1), which can regulate pro-invasive EMT target genes including matrix metalloproteases and vimentin (Reichert et al., 2000; Polette et al., 2007) . Because of its clear on and off regulation during EMT events, vimentin is considered a reliable marker of EMT. Several extracellular signals have been shown to trigger EMT processes through specific signaling pathways including epidermal growth factor (EGF), transforming growth factor (TGF)-b, hepatocyte growth factor (HGF), wnt/b-catenin, hedgehog and notch. These pathways interact and converge onto a number of specific transcriptional factors that contribute to the regulation of EMT target genes. These transcriptional factors include Snail, Slug, SIP1 (smad-interacting protein 1, ZEB2), d-EF1 (delta-crystallin enhancer factor 1, ZEB1), E12/E47 or twist. A major target of these factors is E-cadherin, upon which they directly or indirectly act as strong repressors (Peinado et al., 2007; Yang and Weinberg, 2008; Vandewalle et al., 2009) .
A massive amount of in vitro data has clearly established that EMT-derived cells display higher migratory and invasive properties but in vivo data demonstrating the involvement of EMT processes in the metastatic dissemination are still scarce. Nevertheless, in humans, EMT phenotypes have been detected in a variety of human primary carcinomas and have been associated with poor survival (Guarino et al., 2007; Sarrio et al., 2008) . A few studies have also reported reduced expression of epithelial molecules and/or increased mesenchymal gene expression in breast cancer CTCs (Aktas et al., 2009; Kallergi et al., 2011; Mego et al., 2011; Raimondi et al., 2011) . Because of the difficulty in following dynamic EMT processes in human tumors and because of the difficulty to characterize CTCs in humans (Paterlini-Brechot and Benali, 2007; Pantel and Alix-Panabieres, 2010 ), it appears today very complementary and necessary to develop animal model systems to evaluate and dissect the functional implications of specific EMT processes in vivo in specific stages of the metastatic progression.
In the present study, we have developed and characterized an animal model with transplantable human breast tumor cells uniquely capable of spontaneous EMT events, which occur and reverse in vivo. We have then examined the relationship between EMT processes and different stages of metastatic spread in this model.
Results

MDA-MB-468 as an inducible model of EMT in vitro
In order to characterize a model allowing the in vivo study of EMT, we first screened different human breast tumor cell lines displaying an epithelial phenotype for their potential ability to undergo EMT after various stimuli in vitro. We found that EMT changes could be induced by EGF in MDA-MB-468 cells, as also previously reported (Lo et al., 2007) . A clonal cell line expressing luciferase and green fluorescent protein (GFP) was generated (468-LUC) and used for subsequent experiments. As shown in Figure 1 , a dosedependent appearance of vimentin expression and a diminution of E-cadherin were observed both at the mRNA ( Figure 1a ) and protein level (Figures 1b and c) . Examining other well known EMT players, we observed an increase of the master EMT transcriptional factors Snail and Slug, and of the mesenchymal marker FSP1 (Figure 1d ). Inversely, a diminution of several other cellcell contact adhesion molecules was observed, such as JAM-A or ZO-3 (Figure 1d ). These data thus clearly showed that the 468-LUC cells were susceptible to undergo EMT changes under appropriate stimuli.
Transwell invasion assays further showed that 468-LUC cells displayed enhanced invasive abilities in the presence of EGF (Figure 1e ). EGF treatment was also correlated to an increased vimentin/glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ratio as measured by RT-qPCR (reverse transcriptase-quantitative PCR) (Figure 1f) , emphasizing a functional consequence of EMT induction in our model.
MDA-MB-468 as an inducible model of EMT in vivo
In light of these in vitro results, we examined the 468-LUC cells in vivo and followed their metastatic behaviour using the IVIS 200 in vivo imaging system. The cells were injected s.c. in the flank of severe combined immunodeficiency disease (SCID) mice to study their metastatic potential in relation to eventual changes in phenotype of the primary tumors. Primary tumors were detectable 8 days after inoculation, and enlarged progressively. In order to evaluate tumor heterogeneity in relation to EMT, we examined the expression of the EMT marker vimentin in primary tumors. This was first done in a pilot setting of 20 mice, 10 of which were killed 8 days after injection for early observation and 10 of which were killed >100 days after injection, when metastases developed (see below). A clear heterogeneity was observed in all primary xenografts with distinguishable vimentin-positive areas and vimentin-negative areas (Figure 2b ). Consolidating the relevance of these observations, vimentin/keratin double immunostainings performed on invasive human triplenegative breast cancer biospies similarly revealed a heterogeneous pattern of vimentin expression with areas of keratin-positive tumor cells expressing vimentin and areas with vimentin-negative cells in all 10 biopsies (Figure 2a ). In contrast, examining 10 biopsies of luminal breast cancers reveal vimentin expression in only one biospy (data not shown). This is in agreement with the literature data associating EMT phenotypes to the basal/triplenegative subgroups of breast cancers (Sorlie et al., 2001; Livasy et al., 2006; Rakha et al., 2006; Sarrio et al., 2008) .
To further characterize the phenotypic heterogeneity of the primary 468-LUC xenografts in more detail, microdissection was performed to isolate and compare vimentin-positive areas with vimentin-negative areas. RT-PCR (reverse transcriptase-PCR) screening for EMT markers was then performed on RNA extracted from these two microdissected zones. As shown in Figure 2c , Snail, Slug and FSP1 were overexpressed in the vimentin-positive areas whereas E-cadherin, JAM-A and ZO-3 were decreased, concordant with the EGF-induced EMT in vitro.
MDA-MB-468 as a metastatic model in vivo generating CTCs A periodical follow up with the IVIS 200 revealed luminescent signals outside of the primary tumor areas around 3 months (>100 days) after inoculation. Mice were killed when signals were observed in the lung area (Figure 3a) . At the time of killing, all the 10 animals harbored luminescent signals in the lung (Figure 3b ). In all, 30% of the mice also displayed signals in the liver (Figure 3b ). Histological sections and specific antihuman Ki67 labeling confirmed the presence of lung metastases and liver metastases in organs with luminescent signal (Figure 3c ). Performing Luciferase immunohistochemistry on serial sections in the organs revealed that the Luciferase and the Ki67 stains clearly labeled the same population, showing that the Ki67 staining can also be used to label the whole population of 468-LUC cells (Figure 3c ).
In order to follow up the dynamic generation of CTCs and formation of metastases, we performed time course experiments. Groups of five mice were thus killed periodically starting as early as 4 days after injection and analyzed with the IVIS 200. Chemiluminescent signals in the lungs were observed as early as 24 days after injection (Figures 4a and b) . Ki67 immunostaining of the lungs revealed that chemiluminescent signals detected in the lungs at earlier time points (from 24 to 65 days after injection) correspond to the presence of isolated tumor cells (Figure 4c ). Overt lung metastases could only be observed at the later time points (128 and 176 days) after injection, which correlates well with the significant increase of chemiluminescence observed in the lungs at these later time points. Blood was also collected at each time point to evaluate the presence of CTCs by performing a RT-PCR specific for human GAPDH. Thus, CTCs were detectable as early as 8 days after injection and obviously increased at later time points (Figures 5Aa and 5Ab ) particularly 36 days after injection, after which their levels remained quite constant. Interestingly, this peak in CTC level at 36 days after injection coincided quite nicely with tumor growth ( Figure 5B ) and with an increase of vimentinpositive total area in the primary tumors ( Figure 5C ). Indeed, scanning vimentin-immunolabeled slides and Figure 5C ).
In order to undoubtedly demonstrate the presence of CTCs in our model, we injected another group of 10 mice with 468-LUC cells and used EpCAM antibody-coated magnetic beads (Dynal, CELLection epithelial enrich kit, Invitrogen Dynal AS, Oslo, Norway) to isolate CTCs from the blood. We were thus able to visualize purified green cells in the blood demonstrating the presence of CTCs in the blood (Figure 5Ac ).
In the light of the heterogeneity observed in the primary tumor xenografts for vimentin and other EMT markers, we aimed at better characterizing the CTCs by nested RT-qPCR. RNA was thus extracted from the blood of another group of 10 mice injected for 36 days with 468-LUC cells. We first estimated the number of CTCs to range between 4 and 27 CTCs in the blood samples. This was done by reporting the hGAPDH value obtained by nested RT-qPCR in RNA extracted from the blood samples to a hGAPDH standard curve established by spiking increasing number of 468-LUC cells (10, 50, 75, 100, 500, 750 and 1000 cells) ex-vivo in naive mouse blood.
By performing nested RT-qPCR using specific human primers for vimentin, Snail and Slug, we next characterized the CTCs for the expression of these EMT markers. RNA extracted from the blood of the 10 mice injected with 468-LUC was compared with RNA extracted from naive mouse blood spiked ex vivo with the following cells as controls: 468-LUC cells, 468-LUC cells treated with EGF (which was shown to induce vimentin protein expression in about 20% of the cells after 48 h of treatment (data not shown) and MDA-MB-231 cells (a cell line known to express high basal levels of vimentin in the entire cell population). As shown in Figure 6a , CTCs from all 10 mice EMT in CTC and metastasis formation A Bonnomet et al examined expressed high levels of vimentin mRNA, B4 times more than the spiked EGF-treated 468-LUC cells. Similarly, we also examined the two EMT transcriptional factors Snail and Slug. Interestingly, in contrast to vimentin, which was found expressed in the CTCs from all mice, Snail and Slug expression was found in a restricted number of mice (3 out of 10 mice for Snail and 4 out of 10 mice for Slug). Adding to this, the CTCs expressing Snail (Figure 6b) were not necessarily found in the same mice as those expressing Slug (Figure 6c ). (C) Quantification of the total surface of vimentin-positive areas on vimentin immunohistochemistry performed on sections of primary tumors collected from SCID mice injected with 468-LUC cells for 4 days (D4) or 36 days (D36). The entire sections were scanned with a fully automated digital microscopy scanning system. The vimentin-positive surface area was normalized to the total tumor surface area for each section (**Po0.01).
We next more precisely examined intravascular emboli in order to study further our observations that CTCs express vimentin. We thus particularly looked for intravascular emboli early after inoculation (8 days) in a set of 40 mice inoculated with MDA-MB-468 xenografts, using double Von Willebrand (VWF)/vimentin labeling of primary tumors. Of the 40 mice analyzed, 50 intravascular emboli of 468-LUC cells were clearly identified. All cells in these emboli were positive for vimentin ( Figure 7A ), suggesting that EMT phenotypes are associated with intravasation and the generation of CTCs. In the lungs of 40 mice killed >100 days after inoculation, tumor cells in blood vessels could be observed but less frequently than in the primary tumors. Thus, two cases of isolated CTCs were observed (Figure 7Ba ). Nineteen lung tumoral emboli (as illustrated in Figure 7Bc ) were also detected, all embedded in fibrin clots, and were also found to be vimentin-positive as in the tumor vascular emboli of the primary xenografts. In the lung parenchyma, tumor cells were mostly found as individual isolated cells or as micrometastases (Figure 7Ca) , and rarely as large metastases (Figure 7Cc ). However, when large lung metastases were observed, vimentin expression was found to again be heterogeneous (Figure 7Cc ), as observed in the primary xenografts and clinical breast tumors. In contrast, E-cadherin expression was more homogeneous ( Figure 7D ).
Discussion
In the present study, we have developed a mouse model in which MDA-MB-468 cells xenografted into SCID mice 'spontaneously' undergo EMT processes in vivo representative of those seen in clinical breast cancers, and recapitulate the different stages of the metastatic spread. We showed that (i) primary tumors are phenotypically heterogeneous and EMT regions are observed in the xenografts, (ii) CTCs are generated and (iii) CTCs and tumors cells in the vascular emboli of the primary tumors express vimentin, used here as a marker to follow EMT in time and space, and (iv) overt metastases become again heterogeneous for vimentin expression, similar to the primary tumors.
Our results clearly showed that the primary tumors formed at the sites of injection are phenotypically heterogeneous. The immunohistochemistry data showing vimentin expression at the border of the tumor clusters, combined with the RT-PCR results screening EMT related genes, provide clear evidence of EMT occurring in the primary tumors. A few animal models have accordingly revealed such EMT traits acquired in vivo. Trimboli et al. (2008) showed an induction of FSP1 promoter activity in some regions of mammary tumors developed in triple transgenic mice bearing the cmyc oncogene controlled by the mammary-specific WAP promoter, the floxed lacz gene and the Cre recombinase controlled by the WAP promoter. EMT traits, characterized by vimentin expression and E-cadherin reduction among other markers, have also been reported in adenomas developed in the multiple intestinal neoplasia mice model or in breast tumors of MMTV/Met transgenic mice (Ponzo et al., 2009) . These data obtained in animal models are EMT in CTC and metastasis formation A Bonnomet et al also supported by our data and other studies on human breast biopsies, which have revealed breast tumor heterogeneity and have shown that EMT-related phenotypes exist in human tumors (Guarino et al., 2007; Klymkowsky and Savagner, 2009) . Immunological data and gene profiling microarray analyses on human breast tumors have more particularly reported EMT features in the basal subtype of breast cancer, which among the five distinguished subtypes is associated with the poorest prognosis, encompassing so-called 'triple-negative' breast cancers lacking estrogen receptor, progesterone receptor and erbB2 (Sorlie et al., 2001; Livasy et al., 2006; Rakha et al., 2006; Sarrio et al., 2008) . EMT traits are even more enriched in the newly defined 'claudinlow' subset of basal-type breast cancer (Herschkowitz et al., 2007; Prat et al., 2010) , a highly aggressive form of breast cancer (Li et al., 2008; Hennessy et al., 2009) . Taken together, these data emphasize the presence of EMT phenotypes in primary tumors and suggest, in agreement with our results, that EMT processes could at least partially contribute to tumor heterogeneity (Klymkowsky and Savagner, 2009) .
If the data mentioned above confirm the existence of EMT phenotypes in primary tumors, our results further suggest an implication of EMT-derived phenotypes in specific stages of the metastatic progression (that is, 
EMT in CTC and metastasis formation
A Bonnomet et al intravasation and CTC formation). Studies have shown that modifying certain EMT-related genes (that is, cDNA transfection, RNAi inhibition of EMT transcription factors) in tumor cell lines alters their overall ability to disseminate from primary tumors formed in mice (Zhang et al., 2008; Kudo-Saito et al., 2009) . Also, using an elegant double transgenic mice model bearing the GFP gene controlled by the FSP1 promoter and the middle T oncogene controlled by the mammary-specific promoter MMTV, Xue et al. (2003) have shown that GFP cells arising from the primary tumors developed more lung metastases than the GFP-negative cells, and less metastasis was seen when the fibroblast-specific protein-1-expressing mesenchymal subpopulation of cancer cells were selectively killed. Such models establish a role for EMT processes, and more importantly of particular EMT-related gene products, in the overall process of metastases. Complementing the information generated by such models, our system brings information on the in vivo dynamic of EMT and its association with more particular steps of the metastatic cascade. Our results showing a high level of vimentin mRNA expression in CTCs further suggest an association of EMT processes in the particular steps of intravasation and CTC formation (see also (Bonnomet et al., 2010) for review). This was also further emphasized by our immunostaining results showing vimentin-expressing cells in tumoral emboli in primary tumors. Our results also showed Snail and Slug mRNA expression in the CTCs. Interestingly, the expression of these two factors was found in a restricted number of mice and not in the same mice. This suggests that different EMT transcription factors can be activated in the CTCs. These results illustrate the potential redundancy between EMT transcription pathways that lead to the expression of more ubiquitous EMT target genes such as vimentin. This could reflect alterations in the mechanisms of escape from the primary tumor and/or modulation of EMT gene expression in the bloodstream, generating heterogeneity in CTC phenotypes. In agreement with our data, some studies have reported increased expression of EMT markers, including twist (Aktas et al., 2009; Kallergi et al., 2011) , Snail or Slug (Mego et al., 2011) and vimentin (Kallergi et al., 2011; Raimondi et al., 2011) in CTC-enriched fraction from breast cancer patients. EMT traits have also been described in ex vivo-immortalized disseminated tumor cells (DTC) initially isolated from the bone marrow of breast cancer patients (Willipinski-Stapelfeldt et al., 2005) . As cautiously discussed by some authors, further studies are required to undoubtedly establish the precise nature and origin of these vimentin-expressing cells in the blood and their importance for metastases. Indeed, the identification and the characterization of CTCs in humans with respect to EMT aspects is in itself a problem for the following reasons (Paterlini-Brechot and Benali, 2007; Pantel and Alix-Panabieres, 2010) : there are no specific molecular markers for CTCs, CTCs are extremely rare, EMT mesenchymal markers (that is, vimentin) are highly expressed by normal blood cells leading to a high risk of false positive results, and the purification and identification of CTCs based on epithelial markers might be misleading. The use of animal models such as ours, using transplantation of human cell lines in a mouse background, allowing the use of specific human primers for RT-PCR detection and analysis, bypasses such hitherto unresolved limitations of CTC characterization in humans. Data collected on dynamic animal models is thus essential and complementary to studies performed on humans not only to characterize CTCs better but also to examine CTC biology. Our results thus complement and reinforce those obtained in humans and taken together, these data suggest an involvement of EMT in CTC generation. The implication of EMT phenotypes in later stages of the metastatic cascade remains less precise. Comparing sublines of the T24-TSU-Pr1 human bladder carcinoma cell line, Chaffer et al. (2006) have shown that cells displaying rather epithelial characteristics are more metastatic when intracardiac injection are performed, whereas they form less metastases when injected s.c.. In another work, Tsuji et al. (2008) developed a model of hamster oral keratinocytes (HPCP-1) transformed in vitro by a downstream effector of the TGF-b pathway (p12 CKD2ÀAP1 ), which consequently caused EMT traits. Following s.c. injection in mice, the authors found that only p12 CKD2ÀAP1 EMT þ cells were able to reach the blood vessels, in agreement with our observations supporting the involvement of EMT in intravasation. In contrast, when i.v. injections were performed, the authors found that only non-EMT cells developed lung metastases. Furthermore, Tsuji et al. (2008 Tsuji et al. ( , 2009 reported cooperativity when co-inoculation of the two cell sublines was performed, resulting in lung metastases comprising only non-EMT cells . Though our observations do not exclude the possibility that such cooperation exist in humans, our system allowing dynamic plasticity (induction and reversion of EMT), showing that all cells found in emboli are vimentin-positive, suggest at least that such cooperation is not necessary in all systems. Together with our observation showing heterogenous vimentin expression in overt metastases, these studies suggest that an epithelial phenotype is favorable in the latter stages of the metastatic cascade and in the metastasis growth. Along these lines, a recent study has shown that miR200 expression, rather known to inhibit EMT and favor an epithelial phenotype, is required for metastatic competence in the 4T1 mouse mammary carcinoma model (Korpal et al., 2011) . Overexpression of the miR200 reduced the CTC burden in this model; however, this was more than compensated by the ability of the cells to form viable metastases. Our data further support a dynamic occurrence of mesenchymal-to-epithelial transition (MET) processes in this particular stage of metastatic growth. Accordingly, Chao et al. (2010) showed that the highly invasive and metastatic MDA-MB-231 cells undergo mesenchymalepithelial reverting transitions when forming liver metastases. The importance of MET in lung metastases formation has also been emphasized in a Dunning rat model, which led the authors to conclude that what makes cells highly aggressive is not their mesenchymal character per se but rather their capacity to undergo phenotypic transitions (Oltean et al., 2006) . Whether the low potential of EMT cells to develop overt metastases in different models reflects an inability to extravasate or to proliferate in the secondary organs remains questionable. There may indeed be model-specific constraints against dynamic plasticity of the in vitro modified cell systems, which underpin the weak ability of EMT cells to form metastases. Our observation that emboli in the lung also expressed vimentin suggest that at least some EMT-derived characteristics remain during extravasation, but that MET actually occurs when overt metastases develop. Thus, it is important to keep collecting observations on dynamic systems to decipher better the contribution of EMT/MET processes in extravasation and metastatic growth.
In conclusion, our data uniquely illustrate the in vivo dynamic of EMT phenotypic changes that accompany metastatic spread. They suggest that EMT occurs in the primary tumors, providing the cells with an enhanced ability to intravasate and generate CTCs. Once cells have extravasated, MET phenomena would occur to favor the metastatic growth in secondary organs, emphasizing the transient and reversible nature of EMT processes.
Materials and methods
Cell culture
Human breast cancer MDA-MB-468 and MDA-MB-231 cells, obtained from ATCC (American Type Culture Collection, Manassas, VA, USA), were cultured in DMEM (Gibco, Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum (Gibco). A clone of the MDA-MB-468 cells expressing luciferase (referred to as 468-LUC) was generated following transfection by electroporation of pCDNA-3-zeo-LUC (Invitrogen). Because a double transfection was performed with the pIRES-EGFP expression vector (Clontech, Mountain View, CA, USA), this clone also expressed GFP as a fluorescent marker. For EGF treatment, 468-LUC cells were plated into six-well plates in the presence or absence of increasing EGF concentrations (from 1 to 100 ng/ml, Sigma, St Louis, MO, USA) for 96 h.
Transwell invasion assay
The in vitro invasive properties of cells were assessed using a matrigel-coated Transwell invasion assay (BD BioCoat Matrigel Invasion Chamber, BD Biosciences, Bedford, MA, USA). A total of 10 5 cells were placed in the upper compartment of the invasion chamber in serum-free medium. The lower chamber was filled with fetal calf serum-containing growth medium. EGF was added at a concentration of 20 ng/ ml in both compartment. The chambers were incubated for 18 h at 37 1C. The filters were then fixed in methanol and stained with hematoxylin. Quantification of the invasion assay was performed by counting the number of cells on the lower surface of the filters (30 fields at 40-fold magnification).
Animal studies: inoculations and IVIS200 analyses 2 Â 10 6 468-LUC cells were inoculated s.c. with Matrigel into the flanks of six-week-old female immunodeficient SCID mice as previously described (Noel et al., 1993) . Tumor growth was assessed by measuring the length and width of tumors every 10-15 days. Tumor volumes were estimated using the formula: length Â width 2 Â 0.4. In vivo imaging was performed using an IVIS 200 imaging system (Xenogen-Caliper, Hopkinton, MA, USA) as recommended by the manufacturer following i.p. injection of luciferine (Promega, Madison, WI, USA). In all cases, at the time of killing, tumors and organs were collected and analyzed with the IVIS 200 system after which samples were processed either for immunohistochemistry or laser capture microscopy. Densitometric analyses were performed with the living image software of the IVIS 200 to quantify the chemiluminescent signals in the organs. In some experiments, cardiac puncture was also performed to collect blood samples (500 ml), and subsequently perform RNA extraction and RT-PCR or EpCAM antibody-coated immunobead purification.
Immunohistochemistry on mouse tissues
Immunohistochemistry was performed on tumors, lungs or livers fixed in 4% buffered formalin. For Ki67, E-cadherin or luciferase single immunolabelings, sections were incubated with a specific mouse anti-human Ki67 (Clone MIB-1, 1/100, Dako, Glostrup, Denmark) or a mouse anti-E-cadherin antibody (1/100, BD Biosciences Transduction laboratories, San Jose, CA, USA) or a goat anti-luciferase antibody (1/ 10 000, Chemicon, Temecula, CA, USA). The slides were then exposed to horseradish peroxidase (HRP)-coupled anti-mouse IgG (Envision HRP anti-mouse system, Dako) for E-cadherin and Ki67 detection. For luciferase detection, slides were incubated with a biotin-conjugated anti-goat IgG (Dako) followed by an HRP-streptavidin (Dako). The revelation was performed with the DAB þ kit (Dako).
For the double immunostainings presented in Figure 7 , labeling with each antibody was successively performed. The revelations of the different antibodies were performed with different color combination to enhance the contrast between the two labelings. These combinations are detailed in the Supplementary technical informations. The first antibody of interest was either a mouse monoclonal anti-vimentin (clone V9, 1 : 750, Dako) or an anti-human Ki67 (Clone MIB-1, 1/100, Dako). The second antibody of interest was either a rabbit polyclonal anti-VWF (1 : 500, Dako) or the mouse monoclonal anti-vimentin (clone V9, 1 : 750, Dako). In some cases (as specified in the Figures), the sections were finally counterstained in hematoxylin and coverslipped.
Immunohistochemistry on human tissues
Human breast tissues were obtained from 10 biopsies of invasive triple-negative breast carcinomas (8 biopsies of grade 3 and 2 biopsies of grade 2) and 10 biopsies of luminal breast carcinomas (8 biopsies of grade 1 and 2 biopsies of grade 2) selected from an existing characterized breast tumor bank. The samples were fixed in formalin and embedded in paraffin. For vimentin/keratins double staining, sections were incubated with the mouse monoclonal anti-vimentin (clone V9, 1 : 750) followed by the Powervision Plus Poly AP anti IgG system (Immunologic, Duiven, The Netherlands). The revelation was performed with the Vector Blue Alkaline Phosphatase Substrate Kit (Vector Laboratories, Burlingame, CA, USA). Sections were then successively incubated with a rabbit antikeratin antibody (Clone Z622 1:100, Dako) and an HRPconjugated swine anti-rabbit antibody. The revelation was performed with the DAB þ kit (Dako). The sections were finally counterstained in hematoxylin and coverslipped.
Immunofluorescence Subconfluent monolayers of 468-LUC cells were cultured on glass coverslips and were permeabilized with ice-cold methanol. The cells were then incubated with either an anti-Ecadherin (1:25) (clone 36, Transduction Laboratories, BD) or the anti-vimentin antibody (1:20) (clone V9, Dako). Cells were next incubated with an Alexa Fluor 488-coupled anti-mouse IgG (1:200) (Molecular Probes, Eugene, OR, USA). Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (Molecular Probes).
Laser capture microdissection For laser capture microdissection experiments, serial frozen sections of primary 468-LUC tumors were either mounted onto uncoated glass slides for immunohistological analysis (for the first slide of each series) or on Palm Membrane slide (PALM technologies AG, Bernried, Germany) for laser capture microdissection analysis. The first slide of each series was fixed in 95% ethanol for 2 min and processed for vimentin immunolabeling by incubating the slide with the anti-vimentin antibody, and then with an HRP-conjugated anti-mouse IgG (Dako). The revelation was performed with the DAB þ kit (Dako).
The remaining unfixed sections in each series were placed on the laser capture microscope stage (PALM Microlaser Systems, Germany) and vimentin-positive and negative areas (referenced from the immunolabeled slides) were separately microdissected. The selected areas of tissues were then catapulted into a collection tube containing 100 ml of Trizol Reagent (Invitrogen), and RNA was further purified using the RNeasy Minikit (Quiagen, Valencia, CA, USA).
Quantification of the surface of vimentin-positive areas in primary tumors Virtual images of vimentin-labeled primary tumors were acquired with the fully automated digital microscopy system dotSlide (Olympus, BX51TF, Aartselaar, Belgium) coupled with a Peltier-cooled high-resolution digital color camera (1376x1032 pixels) (Olympus, XC10, Aartselaar, Belgium). This system allowed us to digitalize the entire tumor sections. The vimentin-positive areas were then manually delimited using the Photoshop software and the total vimentin-positive surface area was normalized to the surface area of the tumor for each slides.
Blood processing
Whole blood samples (500 ml) were processed for hemolysis in lysis buffer (NH 4 Cl, KCl, EDTA 0.5 M, Tris 1 M, pH 7.4). After centrifugation, cell pellets were processed for total RNA extraction using the Nucleospin RNA II kit (Macherey-Nagel, Du¨ren, Germany) as recommended by the supplier. For vimentin expression analysis in CTCs, control cells (100 cells in 500 ml of blood) were spiked ex vivo in naive mouse blood, and the samples were treated as described above.
EpCAM antibody-coated bead purification was performed on whole blood sample using the CELLection Epithelial Enrich kit (Invitrogen), as recommended by the manufacturer. Purified cells were then spread on a glass slide and coverslipped before they were observed for GFP expression.
Reverse transcription-polymerase chain reaction End point RT-PCR was performed for all analyses except those examining vimentin, Slug and Snail expression in CTCs ( Figure 6 ) and those shown in Figure 1f . End point RT-PCR was performed with 10 ng of total RNA for in vitro experiments and 50 ng for blood-extracted samples using the Thermostable rTth Reverse Transcriptase RNA PCR kit (Applied Biosystem, Foster City, CA, USA) and different pairs of nucleotides (Eurogentec, Seraing, Belgium). The sequences of the primers are shown in Supplementary technical information. RT-PCR products were separated by acrylamide gel electrophoresis, stained with SYBR Gold (Molecular Probes), and quantified by fluorimetric scanning (LAS-4000, Fuji, Stamford, CT, USA).
Vimentin, Snail and Slug expression in CTCs (Figure 6 ) was quantified and normalized to GAPDH by two rounds of PCR (RT-PCR coupled to nested qPCR) using the UPL-probe system (Roche Diagnostics, Basel, Switzerland). In the first round, a RT-PCR was performed for 15 cycles, as described above for endpoint RT-PCR. The sequence of the humanspecific primers used is given in the Supplementary technical information. One tenth of this reaction was then submitted to a second round of amplification by qPCR using the UPL universal probe library system and set of human-specific nested primers. The sequence of these nested primers is also provided in Supplementary technical information. qPCR reactions were performed using the 'Fast Start Universal Probe Master' kit as recommended by the manufacturer, in the LightCycler 480 Instrument (Roche Diagnostics). Each sample was quantified using a standard curve made of serial dilutions of a batch of human placental cDNA (made with the 'Transcriptor First Strand cDNA Synthesis' kit, Roche).
Results presented in Figure 1f were obtained by a one-step qPCR performed with the UPL-probe system as detailed above on cDNA generated from 468-LUC (treated or not with EGF) with the 'Transcriptor First Strand cDNA Synthesis' kit (Roche).
The specificity of each pair of primers for human RNA was tested by end point RT-PCR using two mouse controls: RNA extracted from mouse blood and RNA extracted from a mouse embryo. Adding to this, for CTC characterization, an RNA sample extracted from naive mouse blood was included in all PCR runs and was always negative.
Western blotting
Total proteins were separated on 10% SDS-polyacrylamide electrophoresis gels for analysis of vimentin and E-cadherin, respectively, and were transferred to PVDF membranes (NEN, Boston, MA, USA). The membranes were then incubated with either a mouse anti-E-cadherin antibody (1:2500, Transduction Laboratories) or a mouse anti-vimentin antibody (1:400, clone V9, Dako). The filters were then incubated with an HRPconjugated swine anti-mouse IgG (1:200, Dako). Signals were detected with an enhanced chemiluminescence (ECL þ ) kit (Amersham, GE Healthcare, Buckinghamshire, UK). Subsequent detection of GAPDH (using a mouse antibody, 1:300, clone 6C5, Chemicon, Millipore, Billerica, MA, USA) was performed on the same filters as a control. Analyses were performed by densitometric scanning (LAS-4000).
Statistical analysis
The statistical significance of the variations measured for the EGF dose response experiment (Figures 1a and b) , CTC detection ( Figure 5Ab ) and lung metastasis formation (Figure 4b Figure 5C were analyzed by a Mann-Whitney test. A P-value p0.05 was considered significant.
